Dr. Reddy's Laboratories vs Smith & Nephew
Dr. Reddy's Laboratories (RDY), health care, and Smith & Nephew (SNN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Smith & Nephew is worth $12.8B on the stock market and Dr. Reddy's Laboratories $12.3B: Smith & Nephew is valued at 3% more. Dr. Reddy's Laboratories trades at 41.1 times earnings and Smith & Nephew at 20.8; operating margins in their latest fiscal years were 15.0% and 12.9%. Over the past year Dr. Reddy's Laboratories's share price has moved +4.85% and Smith & Nephew's -4.82%.
Key facts
- Dr. Reddy's Laboratories market value
- $12.3B
- Smith & Nephew market value
- $12.8B
- Dr. Reddy's Laboratories P/E
- 41.1
- Smith & Nephew P/E
- 20.8
- Dr. Reddy's Laboratories revenue
- $3.6BFY to 2026-03-31
- Smith & Nephew revenue
- $6.2BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Dr. Reddy's Laboratories | Smith & Nephew |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2026-03-31 | 2025-12-31 |
| Size | ||
| Market cap | $12.3Blower | $12.8Bhigher |
| Revenue | $3.6Blower | $6.2Bhigher |
| Earnings | $456Mlower | $625Mhigher |
| Employees | 27,527higher | 17,000lower |
| Total assets | $6.2Blower | $10.5Bhigher |
| Valuation | ||
| P/E | 41.1higher | 20.8lower |
| P/S | 3.4higher | 2.1lower |
| P/B | — | — |
| Dividend yield | — | — |
| Profitability | ||
| Operating margin | 15.0%higher | 12.9%lower |
| Balance sheet | ||
| Net assets | $4Blower | $5.3Bhigher |
| Total liabilities | $2.1Blower | $5.2Bhigher |
| Total debt | $193.7Mlower | $3.1Bhigher |
| Cash on hand | $163.5Mlower | $557Mhigher |
| Price change | ||
| Today | +0.61%higher | -1.49%lower |
| 1 year | +4.85%higher | -4.82%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Dr. Reddy's Laboratories only (0)
None of the tracked investors.
Smith & Nephew only (2)
Percentages are each holding's share of that investor's reported portfolio. Who owns RDY · Who owns SNN
More on Dr. Reddy's Laboratories
Further comparisons
Dr. Reddy's Laboratories against its closest peers
Smith & Nephew against its closest peers
Learn
Questions and answers
Which is bigger, Dr. Reddy's Laboratories or Smith & Nephew?
By market value, Smith & Nephew is the larger: $12.8B against $12.3B for Dr. Reddy's Laboratories. By revenue in its latest fiscal year, Smith & Nephew is the larger: $6.2B against $3.6B for Dr. Reddy's Laboratories.
Which has the higher P/E ratio?
Dr. Reddy's Laboratories: 41.1, against 20.8 for Smith & Nephew. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Dr. Reddy's Laboratories: 15.0%, against 12.9% for Smith & Nephew. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Smith & Nephew: $3.1B, against $193.7M for Dr. Reddy's Laboratories. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Dr. Reddy's Laboratories and Smith & Nephew?
None of the tracked superinvestors holds both in their latest 13F filing. 0 hold Dr. Reddy's Laboratories and 2 hold Smith & Nephew.
Cite this page
Funkfolio, “Dr. Reddy's Laboratories vs Smith & Nephew”, data as of 18 November 2026. https://funkfolio.com/compare/rdy-vs-snn
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.